BBIO - BridgeBio Pharma Inc
IEX Last Trade
27.86
3.240 11.630%
Share volume: 9,110,089
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$24.62
3.24
13.16%
Fundamental analysis
31%
Profitability
37%
Dept financing
25%
Liquidity
73%
Performance
16%
Performance
5 Days
10.04%
1 Month
7.36%
3 Months
-3.47%
6 Months
-21.08%
1 Year
-8.39%
2 Year
169.34%
Key data
Stock price
$27.86
DAY RANGE
N/A - N/A
52 WEEK RANGE
$21.62 - $44.32
52 WEEK CHANGE
-$0.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Neil Kumar
Region: US
Website: http://bridgebio.com/
Employees: 333
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://bridgebio.com/
Employees: 333
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
Recent news